Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201058 | 1.00 | CA2 (0.50) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL288045 | 1.00 | CA2 (0.50) | CA2MAPK1NOD1GPR84FFAR1 | |
| Hydrochloric Acid SCHEMBL4908040 | 0.98 | CA2 (0.48) | CA2MAPK1NOD1GPR84FFAR1 | |
| Hydrochloric Acid SCHEMBL20361641 | 0.98 | CA2 (0.48) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL24709075 | 0.93 | GPR84 (0.52) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL21102191 | 0.93 | GPR84 (0.52) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL15451410 | 0.93 | GPR84 (0.52) | CA2MAPK1NOD1GPR84FFAR1 | |
| SCHEMBL20366017 | 0.91 | GPR84 (0.55) | NOD1GPR84FFAR1MAPTLCK | |
| SCHEMBL25208251 | 0.91 | GPR84 (0.55) | NOD1GPR84FFAR1MAPTLCK | |
| SCHEMBL3896154 | 0.91 | GPR84 (0.55) | NOD1GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161408-A1 | PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2025-05-22 | — | — | US | claimed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| CN-118632867-A | GLP-1/GIP receptor co-agonist prodrugs and uses thereof | 诺和诺德股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-03-14 | — | — | US | claimed |
| EP-4230645-A1 | PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY | Technische Universität München (DE) | 2023-08-23 | — | — | EP | claimed |
| WO-2023139187-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | claimed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | claimed |
| US-20220241377-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | Molgenie GmbH (DE) | 2022-08-04 | — | — | US | claimed |
| EP-4003403-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | Molgenie GmbH (DE) | 2022-06-01 | — | — | EP | claimed |
| CN-114450299-A | Receptor-targeting peptide-drug conjugates | 莫尔吉尼有限责任公司 | 2022-05-06 | — | — | CN | claimed |
| EP-1506221-A2 | FAP-ACTIVATED ANTI-TUMOR PRODRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-02-16 | — | — | EP | claimed |
| EP-1472277-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-03 | — | — | EP | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| US-20040033957-A1 | FAP-activated anti-tumor prodrugs | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-19 | — | — | US | claimed |
| WO-2003094972-A2 | FAP-ACTIVATED ANTI-TUMOR PRODRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20030211979-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| WO-2003064454-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-08-07 | — | — | WO | claimed |
| EP-1333033-A1 | FAP-activated anti-tumor compounds | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | GIPR, GLP1R, GRPR | CA2 2144/4885MAPK1 2486/4885NOD1 687/4885 |
| US-20220241377-A1 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | NPY1R, NPY2R, NPY5R | CA2 3512/4885MAPK1 2263/4885NOD1 4078/4885 |
| US-20040033957-A1 | FAP-activated anti-tumor prodrugs | FAP, DNPEP, PAICS | CA2 444/4885MAPK1 3876/4885NOD1 691/4885 |
| US-20030211979-A1 | FAP-activated anti-tumor compounds | FAP, FIBP, APC | CA2 737/4885MAPK1 2494/4885NOD1 2007/4885 |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | GIPR, GLP1R, GRPR | CA2 2144/4885MAPK1 2486/4885NOD1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.